I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her ...

Risk for pancreatitis was not elevated among users of tirzepatide relative to placebo, despite the presence of elevated pancreatic enzymes.

Eli Lilly said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the ...

Popular obesity stocks fell on Tuesday after pharma giant Eli Lilly LLY lowered its sales guidance for full-year 2024 and announced disappointing preliminary fourth-quarter sales numbers. LLY’s ...

Ready to crush your New Year’s health goals? These breakthrough medications offer more than weight loss—they support your ...

Patients with overweight or obesity who used maridebart cafraglutide experienced significant weight loss at 1 year, according ...

Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.

Blood glucose reduction and insulin secretion levels from the oral DehydraTECH-tirzepatide were comparable to injected Zepbound® KELOWNA, BC / ACCESSWIRE / January 14, 2025 / Lexaria Bioscience ...

Lexaria Bioscience (LEXX) announces partial final results showcasing the tolerability and glycemic control efficacy findings from human study ...

New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering ...

After plugging billions into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...